A combined treatment for acute larger lacunar-type infarction

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
Yasumasa YamamotoRyo Oohara

Abstract

Larger lacunar-type infarcts (LLIs), presumably caused by occlusion at the orifices or proximal portions of larger-caliber penetrating arteries by atheromatous plaque, are frequently associated with progressive motor deficits (PMD) and lead to poor functional outcome. This study was conducted to examine the efficacy of a combined treatment to prevent PMD or improve the functional outcome in patients with LLI. A total of 218 consecutive patients with LLI and motor lacunar syndrome were enrolled, including 138 patients with infarcts in the territory of the lenticulostriate artery and anterior choroidal artery (supratentrial group) and 80 patients with infarcts in the territory of the anterior pontine artery (pontine group). The prevalence of PMD and functional outcome represented by modified Rankin Scale (mRS) score at 1 month after ictus were compared between groups treated with a combined treatment approach consisting of cilostazol and edaravone (n = 100) and a conventional treatment approach (n = 118). The efficacy of the combined treatment provided in 2005-2009 was compared with conventional treatment provided in 2001-2005. There was no significant difference in the prevalence of PMD between the 2 treatment groups. The combin...Continue Reading

References

Apr 1, 1988·Stroke; a Journal of Cerebral Circulation·K AbeK Kogure
Jul 1, 1988·Prostaglandins, Leukotrienes, and Essential Fatty Acids·T WatanabeS Murota
Apr 1, 1973·Journal of Neuropathology and Experimental Neurology·S M Aronson
Sep 1, 1971·Neurology·C M Fisher, L R Caplan
Jul 15, 1983·European Journal of Pharmacology·J NaitoM Tsuboshima
Jan 1, 1996·Neurology·C BassettiF Regli
Apr 30, 1998·Archives of Neurology·H YamamotoG van Melle
Jun 20, 1998·Neurology·L TatuH Duvernoy
Jan 14, 1999·Diabetes Research and Clinical Practice·M IwaseM Fujishima
Jan 28, 1999·Neurology·K NakamuraM Fujishima
Apr 6, 2002·Stroke; a Journal of Cerebral Circulation·Mar CastellanosAntoni Dávalos
Jun 8, 2002·Stroke; a Journal of Cerebral Circulation·Wolfgang Steinke, Stephan C Ley
Mar 8, 2003·Stroke; a Journal of Cerebral Circulation·Ralf W BaumgartnerDimitrios Georgiadis
May 13, 2003·Journal of Atherosclerosis and Thrombosis·Koji OidaIsamu Miyamori
May 25, 2004·Stroke; a Journal of Cerebral Circulation·Marian P LaMonteUNKNOWN ARGIS-1 Investigators
Feb 28, 2008·Cerebrovascular Diseases·Soo Kyoung KimGyeong-Moon Kim
Oct 20, 2009·Journal of the Neurological Sciences·Yasumasa YamamotoKotaro Ozasa

❮ Previous
Next ❯

Citations

Apr 3, 2012·International Journal of Stroke : Official Journal of the International Stroke Society·Alessandra Del BeneDomenico Inzitari
Dec 19, 2012·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Ichiro DeguchiNorio Tanahashi
May 21, 2016·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Mariko TakeuchiKazuyuki Nagatsuka
Jul 19, 2017·Frontiers in Neurology·Robert W RegenhardtThabele M Leslie-Mazwi
Sep 26, 2020·Clinical Neurology and Neurosurgery·Shumin ChenHao Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.